Table 1 Characteristics of the ITT population (n = 231) at baseline, according to neoadjuvant regimen.
Characteristic | Total, n = 231 | Chemotherapy, n = 78 | Immunochemotherapy, n = 153 | P-value |
|---|---|---|---|---|
Median age (IQR), years | 65.7 (60.0–71.0) | 63.1 (58.8–68.3) | 67.1 (62.0–72.0) | 0.402 |
Sex, n (%) | 0.510 | |||
Male | 226 (97.8) | 77 (98.7) | 149 (97.4) | |
Female | 5 (2.2) | 1 (1.3) | 4 (2.6) | |
ECOG performance status, n (%) | 0.490 | |||
0 | 156 (67.5) | 55 (70.5) | 101 (66.0) | |
1 | 75 (32.5) | 23 (29.5) | 52 (34.0) | |
Smoking status, n (%) | 0.121 | |||
Never | 62 (26.8) | 16 (20.5) | 46 (30.1) | |
Ever | 169 (73.2) | 62 (79.5) | 107 (69.9) | |
Drinking status, n (%) | 0.433 | |||
Never | 153 (66.2) | 49 (62.8) | 104 (68.0) | |
Ever | 78 (33.8) | 29 (37.2) | 49 (32.0) | |
Comorbidities, n (%) | ||||
Pulmonary disease | 32 (13.9) | 8 (10.3) | 24 (15.7) | 0.463 |
Cardiac disease | 18 (7.8) | 5 (6.4) | 13 (8.5) | 0.576 |
Diabetes mellitus | 23 (10.0) | 11 (14.1) | 12 (7.8) | 0.133 |
Hypertension | 66 (28.6) | 22 (28.2) | 44 (28.8) | 0.930 |
Tumor location, n (%) | 0.878 | |||
Mediastinum | 3 (1.3) | 1 (1.3) | 2 (1.3) | |
Hilum of left lung | 6 (2.6) | 1 (1.3) | 5 (3.3) | |
Hilum of right lung | 2 (0.9) | 1 (1.3) | 1 (0.7) | |
Inferior lobe of left lung | 34 (14.7) | 13 (16.7) | 21 (13.7) | |
Inferior lobe of right lung | 46 (19.9) | 18 (23.1) | 28 (18.3) | |
Middle lobe of right lung | 14 (6.1) | 3 (3.8) | 11 (7.2) | |
Superior lobe of left lung | 71 (30.7) | 24 (30.8) | 47 (30.7) | |
Superior lobe of right lung | 55 (23.8) | 17 (21.8) | 38 (24.8) | |
Clinical stage, n (%) | 0.699 | |||
IB | 5 (2.2) | 1 (1.3) | 4 (2.6) | |
IIA | 3 (1.3) | 1 (1.3) | 2 (1.3) | |
IIB | 26 (11.3) | 9 (11.5) | 17 (11.1) | |
IIIA | 107 (46.3) | 32 (41.0) | 75 (49.0) | |
IIIB | 90 (39.0) | 35 (44.9) | 55 (35.9) | |
Treatment cycle, n (%) | 0.324 | |||
2 | 86 (37.2) | 34 (43.6) | 52 (34.0) | |
3 | 39 (16.9) | 13 (16.7) | 26 (17.0) | |
4 | 106 (45.9) | 31 (39.7) | 75 (49.0) | |
Immunotherapy regimes, n (%) | NA | |||
Camrelizumab, 200 mg | 49 (21.2) | 0 (0.0) | 49 (32.0) | |
Durvalumab, 1000 mg | 2 (0.9) | 0 (0.0) | 2 (1.3) | |
Nivolumab, 200 mg | 22 (9.5) | 0 (0.0) | 22 (14.4) | |
Sintilimab, 200 mg | 17 (7.4) | 0 (0.0) | 17 (11.1) | |
Tislelizumab, 200 mg | 32 (13.9) | 0 (0.0) | 32 (20.9) | |
Pembrolizumab, 200 mg | 31 (13.4) | 0 (0.0) | 31 (20.3) |
